CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Status:
Recruiting
Trial end date:
2025-04-25
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to
evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive
relapsed or refractory Malignant Hematologic Diseases